TY  - JOUR
AU  - Escudero-Sánchez, Rosa
AU  - Ruíz-Ruizgómez, María
AU  - Fernández-Fradejas, Jorge
AU  - García Fernández, Sergio
AU  - Olmedo Samperio, María
AU  - Cano Yuste, Angela
AU  - Valencia Alijo, Angela
AU  - Díaz-Pollán, Beatriz
AU  - Rodríguez Hernández, María Jesús
AU  - Merino De Lucas, Esperanza
AU  - Martín Segarra, Oriol
AU  - Sáez Bejar, Carmen
AU  - Armiñanzas Castillo, Carlos
AU  - Gutiérrez Gutiérrez, Belén
AU  - Rodríguez-Pardo, Dolors
AU  - Ramos Martínez, Antonio
AU  - De La Torre Cisneros, Julián
AU  - López-Medrano, Francisco
AU  - Cobo Reinoso, Javier
PY  - 2020
DO  - 10.3390/jcm10010002
SN  - 2077-0383
UR  - https://hdl.handle.net/10668/28345
T2  - Journal of clinical medicine
AB  - Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was...
LA  - en
KW  - C. difficile infection
KW  - Clostridioides difficile
KW  - Clostridium difficile
KW  - bezlotoxumab
KW  - recurrence
TI  - Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection.
TY  - research article
VL  - 10
ER  -